Smoking Lung Cancer Patients and Tobacco Cessation – Is the Current Treatment in Germany Sufficient?

Abstract

Lung cancer is the most preventable neoplastic disease for men and women. The incidence rate per year is 14.000 in Germany. Smoking is the main risk factor for the onset of lung cancer and for a share of 90 % of cases, lung cancer is associated with smoking. Recent studies have shown that the time slot of diagnosing lung cancer is a teachable moment for tobacco cessation interventions. The therapy that was rated most effective was a combination of cognitive behavioral therapy and pharmacotherapy (e. g. NRT, Bupropion, Varenicline).

We examined the smoking status of all patients undergoing lung cancer surgery in 2011, 2012 and 2013 in this study. A retrospective semi structured interview via telephone was conducted regarding smoking habits and current quality of life. 131 patients (36.6 % female, average age of 68.7 years) of an urban German hospital were included.

Results showed a relapse rate of 22.3 %, while 86.2 % used to be highly addicted smokers; A multivariate analysis of covariance (MANCOVA) indicated a significant overall impact of smoking status on quality of life with a medium effect size, controlled for age, gender, living conditions, tumor stage, duration of smoking abstinence, type of cancer therapy, type of resection method, and the time period between the date of surgery and of the survey. Two thirds of all smokers did not see an association between their habit and their disease.

So far motivation to quit and long term abstinence rates are not sufficiently established even among seriously sick patients in Germany; further initiatives should focus on new and more intense interventions and educational strategies.

Zusammenfassung

Lungenkrebs ist die vermeidbarste neoplastische Erkrankung für Männer und Frauen. Die Inzidenzrate liegt in Deutschland jährlich bei 14.000. Rauchen ist der Hauptrisikofaktor für Lungenkrebs und in 90% der Fälle mit der Krankheit assoziiert. Studien haben gezeigt, dass der Zeitpunkt der Diagnosestellung ein günstiger Moment für Rauchstopp-Interventionen ist. Die effektivste Therapie-Methode war dabei eine Kombination aus Verhalten- und Pharmakotherapie (z.B. NET, Bupropion, Vareniclin).

In dieser Studie wurde der Rauchstatus aller resezierten Lungenkrebspatienten aus den Jahren 2011, 2012 und 2013 untersucht. Ein retrospektives, halb-strukturiertes Telefoninterview zu Rauchgewohnheiten und Lebensqualität wurde durchgeführt. 131 Patienten (36,6 % weiblich, Durchschnittsalter 68,7 Jahre) einer städtischen, deutschen Klinik wurden eingeschlossen.

Die Ergebnisse zeigen eine Rückfallrate von 22,3 %, wovon 86,2 % stark abhängige Raucher waren. Eine multivariate Analyse der Kovarianz (MANCOVA) zeigte einen signifikanten Einfluss des Rauchstatus auf die Lebensqualität mit mittlerer Effektstärke (kontrolliert nach Alter, Geschlecht, Lebensumstände, Tumorstadium, Dauer der Rauchabstinenz, Art der Krebstherapie, Operationsmethode und Zeitraum zwischen Untersuchung und OP-Termin). Zwei Drittel aller Patienten sahen keinen Zusammenhang zwischen der Erkrankung und ihrem Rauchverhalten.

Bisher wird die Rauchstoppmotivation und die Langzeitabstinenz auch von lebensbedrohlich erkrankten Menschen in Deutschland nicht umfassend berücksichtigt. Zukünftige Forschungsvorhaben sollten sich auf neue und intensivere Interventionen und psychoedukative Strategien konzentrieren.

• References

• 1 Blum T, Schonfeld N, Goeckenjan G et al. [Implementation of the German Guideline for the Prevention, Diagnosis, Treatment, and Follow-up of Lung Cancer in the Federal State of Berlin]. Pneumologie (Stuttgart, Germany) 2013; 67: 118-122
• 2 Batra A. Treatment of tobacco dependence. Deutsches Arzteblatt international 2011; 108: 555-564
• 3 Andreas S, Rittmeyer A, Hinterthaner M et al. Smoking cessation in lung cancer – achievable and effective. Deutsches Arzteblatt international 2013; 110: 719-724
• 4 Cooley ME, Sipples RL, Murphy M et al. Smoking cessation and lung cancer: oncology nurses can make a difference. Seminars in oncology nursing 2008; 24: 16-26
• 5 Cataldo JK, Dubey S, Prochaska JJ. Smoking cessation: an integral part of lung cancer treatment. Oncology 2011; 78: 289-301
• 6 Park ER, Japuntich S, Temel J et al. A smoking cessation intervention for thoracic surgery and oncology clinics: a pilot trial. J Thorac Oncol 2011; 6: 1059-1065
• 7 Fiore MC, Schroeder SA, Baker TB. Smoke, the chief killer – strategies for targeting combustible tobacco use. N Engl J Med 2014; 370: 297-299
• 8 Mong C, Garon EB, Fuller C et al. High prevalence of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessation. Journal of cardiothoracic surgery 2011; 6: 19
• 9 Cooley ME, Emmons KM, Haddad R et al. Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer 2011; 117: 2961-2969
• 10 Cooley ME, Sarna L, Brown JK et al. Tobacco use in women with lung cancer. Ann Behav Med 2007; 33: 242-250
• 11 Cooley ME, Wang Q, Johnson BE et al. Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. Lung cancer (Amsterdam, Netherlands) 2012; 76: 144-149
• 12 Wong WS, Fielding R. Prevalence of chronic fatigue among Chinese adults in Hong Kong: a population-based study. Journal of affective disorders 2010; 127: 248-256
• 13 Daniel M, Keefe FJ, Lyna P et al. Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels. J Pain 2009; 10: 323-328
• 14 Vaporciyan AA, Merriman KW, Ece F et al. Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation. The Annals of thoracic surgery 2002; 73: 420-425 discussion 425–426
• 15 Raupach T, Quintel M, Hinterthaner M. [Preoperative smoking cessation in patients with lung cancer]. Pneumologie (Stuttgart, Germany) 2010; 64: 694-700
• 16 Zaman M, Bilal H, Mahmood S et al. Does getting smokers to stop smoking before lung resections reduce their risk?. Interactive cardiovascular and thoracic surgery 2012; 14: 320-323
• 17 Poghosyan H, Kennedy SL, Cooley ME. The impact of computed tomography screening for lung cancer on smoking behaviors: a teachable moment?. Cancer nursing 2012; 35: 446-475
• 18 Park ER, Japuntich SJ, Rigotti NA et al. A snapshot of smokers after lung and colorectal cancer diagnosis. Cancer 2012; 118: 3153-3164
• 19 Cooley ME, Sarna L, Kotlerman J et al. Smoking cessation is challenging even for patients recovering from lung cancer surgery with curative intent. Lung cancer (Amsterdam, Netherlands) 2009; 66: 218-225
• 20 Parsons A, Daley A, Begh R et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ (Clinical research ed 2010; 340: b5569
• 21 Goeckenjan G, Sitter H, Thomas M et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society – abridged version]. Pneumologie (Stuttgart, Germany) 2011; 65: e51-e75
• 22 de Bruin-Visser JC, Ackerstaff AH, Rehorst H et al. Integration of a smoking cessation program in the treatment protocol for patients with head and neck and lung cancer. Eur Arch Otorhinolaryngol 2012; 269: 659-665
• 23 Loh WY, Piper ME, Schlam TR et al. Should all smokers use combination smoking cessation pharmacotherapy? Using novel analytic methods to detect differential treatment effects over 8 weeks of pharmacotherapy. Nicotine Tob Res 2012; 14: 131-141
• 24 Hering T, Andres J, Gebhardt R et al. [Smoking cessation in pneumological routine care]. Pneumologie (Stuttgart, Germany) 2011; 65: 692-696
• 25 Jimenez-Ruiz C, Berlin I, Hering T. Varenicline: a novel pharmacotherapy for smoking cessation. Drugs 2009; 69: 1319-1338
• 26 Andreas S, Herth FJ, Rittmeyer A et al. [Smoking, chronic obstructive pulmonary disease and lung cancer]. Pneumologie (Stuttgart, Germany) 2007; 61: 590-594
• 27 Cooley ME, Finn KT, Wang Q et al. Health behaviors, readiness to change, and interest in health promotion programs among smokers with lung cancer and their family members: a pilot study. Cancer nursing 2013; 36: 145-154
• 28 Bastian LA, Fish LJ, Peterson BL et al. Proactive recruitment of cancer patients' social networks into a smoking cessation trial. Contemporary clinical trials 2011; 32: 498-504
• 29 Innocenti F, Del Taglia B, Coppa A et al. Quality of life after mild to moderate trauma. Injury 2015; 46: 902-908
• 30 Heun R, Burkart M, Maier W et al. Internal and external validity of the WHO Well-Being Scale in the elderly general population. Acta psychiatrica Scandinavica 1999; 99: 171-178
• 31 Bech P, Olsen LR, Kjoller M et al. Measuring well-being rather than the absence of distress symptoms: a comparison of the SF-36 Mental Health subscale and the WHO-Five Well-Being Scale. International journal of methods in psychiatric research 2003; 12: 85-91
• 32 Heatherton TF, Kozlowski LT, Frecker RC et al. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British journal of addiction 1991; 86: 1119-1127
• 33 Poghosyan H, Sheldon LK, Leveille SG et al. Health-related quality of life after surgical treatment in patients with non-small cell lung cancer: a systematic review. Lung cancer (Amsterdam, Netherlands) 2013; 81: 11-26
• 34 Hering T. [Smoking cessation improves quality of life]. MMW Fortschritte der Medizin 2014; 156: 68-69
• 35 Dobson Amato KA, Hyland A, Reed R et al. Tobacco Cessation May Improve Lung Cancer Patient Survival. J Thorac Oncol 2015; 10: 1014-1019
• 36 Poghosyan H, Bell JF, Joseph JG et al. The association between having a first-degree family history of cancer and smoking status. Preventive medicine 2014; 66: 12-16
• 37 Gu F, Wacholder S, Kovalchik S et al. Time to smoke first morning cigarette and lung cancer in a case-control study. Journal of the National Cancer Institute 2015; 106: dju118
• 38 Regan T, Carey M, Bryant J et al. Prevalence and correlates of current smoking among medical oncology outpatients. Psycho-oncology 2015;
• 39 Weaver KE, Danhauer SC, Tooze JA et al. Smoking cessation counseling beliefs and behaviors of outpatient oncology providers. The oncologist 2015; 17: 455-462
• 40 Warren GW, Cummings KM. Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology. 2015: 359-364
• 41 Nicholson AK, Borland R, Couzos S et al. Smoking-related knowledge and health risk beliefs in a national sample of Aboriginal and Torres Strait Islander people. The Medical journal of Australia 2015; 202: 45-50
• 42 Slatore CG, Au DH, Hollingworth W. Cost-effectiveness of a smoking cessation program implemented at the time of surgery for lung cancer. J Thorac Oncol 2009; 4: 499-504
• 43 Fiore MC, Jorenby DE, Schensky AE et al. Smoking status as the new vital sign: effect on assessment and intervention in patients who smoke. Mayo Clinic proceedings 1995; 70: 209-213
• 44 van der Aalst CM, de Koning HJ, van den Bergh KA et al. The effectiveness of a computer-tailored smoking cessation intervention for participants in lung cancer screening: a randomised controlled trial. Lung cancer (Amsterdam, Netherlands) 2012; 76: 204-210
• 45 Cooley ME, Lundin R, Murray L. Smoking cessation interventions in cancer care: opportunities for oncology nurses and nurse scientists. Annual review of nursing research 2009; 27: 243-272
• 46 Anderson JE, Jorenby DE, Scott WJ et al. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 2002; 121: 932-941
• 47 Raupach T, Merker J, Hasenfuss G et al. Knowledge gaps about smoking cessation in hospitalized patients and their doctors. Eur J Cardiovasc Prev Rehabil 2011; 18: 334-341
• 48 Hildebrand JR, Sastry S. “Stop smoking!” Do we say it enough?. Journal of oncology practice/American Society of Clinical Oncology 2013; 9: 230-232
• 49 Tappin D, Bauld L, Purves D et al. Financial incentives for smoking cessation in pregnancy: randomised controlled trial. BMJ (Clinical research ed) 2015; 350: h134
• 50 Zeng F, Chen CI, Mastey V et al. Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims. Clinical therapeutics 2011; 33: 225-234
• 51 Cahill K, Perera R. Competitions and incentives for smoking cessation. The Cochrane database of systematic reviews 2011; CD004307
• 52 Carr SR, Akerley W, Hashibe M et al. Evidence for a genetical contribution to non-smoking-related lung cancer. Thorax 2015; pii: thoraxjnl-2014-206584